Newcells Biotech specializes in developing induced pluripotent stem cell-derived in vitro models for drug discovery, focusing on human tissue simulations such as retinal, kidney, and lung models. Their services provide critical data on drug efficacy and safety, enhancing the predictive accuracy of pre-clinical studies and facilitating clinical translation.
Funding
$19.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery processes often rely on animal models or simplified in vitro systems that fail to accurately predict human responses, leading to high failure rates in clinical trials. The lack of physiologically relevant human tissue models hinders the development of effective and safe therapies.
Solution
Newcells Biotech develops and provides advanced, induced pluripotent stem cell (iPSC)-derived in vitro models of human tissues, including retinal, kidney, and lung, for drug discovery and development. These models mimic the complexity and functionality of human tissues, offering a more predictive platform for assessing drug efficacy, safety, and mechanisms of action. By using these models, researchers can generate data that more accurately reflects in vivo human outcomes, de-risking drug development and accelerating clinical translation. Newcells Biotech offers both custom assay services and products for in-house studies, enabling comprehensive preclinical drug evaluation.
Target Audience
The primary customers are pharmaceutical and biotechnology companies, as well as academic research institutions, involved in drug discovery and development.
Features
- iPSC-derived retinal organoid and pigmented epithelium models for retinopathies, safety studies, and therapeutic vector assessment.
- Kidney nephron models for toxicity, drug-drug interaction (DDI), and transporter assays.
- Lung airway models for drug candidate screening, fibrotic disease mechanism studies, mucociliary clearance, and compound efficacy testing.
- Bespoke efficacy, safety, disease modeling, and membrane transporter kinetics studies.
- High-content and high-throughput imaging suite for advanced preclinical drug development programs.
- Capability to engineer in vitro models from primary tissues and iPSCs.